Key result
P210-conjugated nanoparticles improve impaired CD4+ T cell activation in PBMCs from ASCVD patients.
Why the study?
While the clinical significance of the P210 antibody response is known, it remained unclear whether patients with ASCVD also exhibit an impaired T cell response to P210.
Does treatment with P210-conjugated nanoparticles improve the impaired CD4+ T cell response to ApoB-100 peptide P210 in PBMCs from ASCVD patients?
Does treatment with P210-conjugated nanoparticles improve the impaired CD4+ T cell response to ApoB-100 peptide P210 in PBMCs from ASCVD patients?
P210-conjugated nanoparticles can reverse the impaired CD4+ T cell response to ApoB-100 peptide P210 seen in ASCVD patients, suggesting a potential immunomodulatory therapeutic strategy for atherosclerosis.
The apolipoprotein B-100 (ApoB-100) peptide P210 (amino acids 3136–3155) is localized within atherosclerotic plaques, and low IgG autoantibody levels against P210 are associated with a higher risk of plaque rupture and myocardial infarction (MI), suggesting that this humoral immunity is protective in atherosclerotic cardiovascular disease (ASCVD). While the clinical significance of P210 antibody response has been shown, it remains unclear whether ASCVD patients also exhibit an impaired T cell response to P210. Thus, we investigated the T cell response to P210 in ASCVD patients and evaluated its potential as a target for therapeutic intervention. Peripheral blood mononuclear cells (PBMCs) collected from ASCVD patients and controls were stimulated with the P210 peptide and evaluated for T cell responses using the Activated Immune Markers (AIM) assay. PBMC from ASCVD patients stimulated with P210 had significantly impaired CD4 + CD69 + CD154 + T cell response which persisted into follow-up a year later. Significantly reduced CD4 + T follicular helper cell responses to P210 were also noted in ASCVD patients. Given the beneficial immunomodulation by P210 nanoparticles (P210-PAM) that resulted in reduced atherosclerosis in mice, we investigated its effect on PBMCs from ASCVD patients. Treatment with P210-PAM significantly improved the impaired CD4 + CD69 + CD154 + and CD4 + CD134 + CD137 + T cell activation in response to P210. The study suggests potential future clinical translation for P210-PAM as an immune-modulation strategy for ASCVD.
No takes yet. Share an insight, caveat, or question.
Dimayuga et al. (2026) studied Atherosclerotic cardiovascular disease (ASCVD). P210-conjugated nanoparticles (P210-PAM) vs. Untreated cells / controls was evaluated on CD4+ T cell activation (CD4+ CD69+ CD154+ and CD4+ CD134+ CD137+). Treatment with P210-conjugated nanoparticles significantly improved impaired CD4+ T cell activation in response to P210 in peripheral blood mononuclear cells from ASCVD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: